Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $39.0714.

GMAB has been the subject of several recent research reports. HC Wainwright lowered their price objective on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Weiss Ratings downgraded shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. Truist Financial raised shares of Genmab A/S to a “strong-buy” rating in a research note on Monday, April 27th. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective on the stock. Finally, Guggenheim decreased their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd.

Genmab A/S Stock Down 0.2%

Shares of NASDAQ GMAB opened at $26.39 on Monday. The stock has a fifty day moving average price of $27.32 and a 200 day moving average price of $29.91. The company has a market cap of $16.45 billion, a P/E ratio of 19.99, a P/E/G ratio of 1.17 and a beta of 0.86. Genmab A/S has a 12-month low of $18.89 and a 12-month high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, May 7th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. The company had revenue of $896.00 million during the quarter, compared to the consensus estimate of $905.77 million. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%. Research analysts anticipate that Genmab A/S will post 1.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Orbis Allan Gray Ltd increased its holdings in Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after purchasing an additional 3,340,456 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of Genmab A/S by 2.7% during the 3rd quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock valued at $335,957,000 after buying an additional 291,538 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of Genmab A/S by 84.4% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock valued at $216,827,000 after buying an additional 3,222,983 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after buying an additional 1,334,919 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Genmab A/S by 23.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock worth $107,580,000 after buying an additional 671,307 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.